[{"orgOrder":0,"company":"Sea Pharmaceuticals","sponsor":"TCG Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"SPM-0404","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Sea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Sea Pharmaceuticals \/ TCG Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Sea Pharmaceuticals \/ TCG Lifesciences"}]

Find Clinical Drug Pipeline Developments & Deals by Sea Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The collaboration aims to advance Sea's lead molecule SPM-0404 and a second-generation molecule SPM-0606, biologically active as dual AMPAR, KAINR antagonists.

                          Brand Name : SPM-0404

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 14, 2024

                          Lead Product(s) : SPM-0404

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : IND Enabling

                          Sponsor : TCG Lifesciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank